Thomas W. Doebber

TL;DR: It is reported that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed.

TL;DR: Novel, non-thiazolidinedione agonists for PPARγ and PPARδ that were identified by radioligand binding assays improve hyperglycemia and hypertriglyceridemia in vivo and are able to potentiate preadipocyte differentiation.

TL;DR: It is established that novel selective PPARgamma modulators can produce altered receptor conformational stability leading to distinctive gene expression profiles, reduced adipogenic cellular effects, and potentially improved in vivo biological responses.

TL;DR: Prevention of diet-induced obesity with concomitant reductions in SCD1 expression and the ratio of oleate to stearoyl-CoA in tissues and plasma and pharmacological inhibition ofSCD1 represents a new target for the treatment of obesity and related metabolic disorders.

TL;DR: It is concluded that T NF-α functions to regulate plasma triglycerides and body adiposity and that although TNF-α contributes to reduced insulin sensitivity in older or obese mice, the absence of TNF -α is not sufficient to substantially protect against insulin resistance in the GTG hyperphagic model of rodent obesity.